Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Old arthritis drug tested against rare tumor syndrome – but trial stalls

NCT ID NCT05605587

First seen Nov 17, 2025 · Last updated Jun 22, 2026 · Updated 22 times

Summary

This study tested leflunomide, a drug used for rheumatoid arthritis, in 3 adults with MEN1 syndrome—a genetic condition that raises the risk of multiple tumors. The goal was to see if 6 months of daily leflunomide could shrink or stabilize tumors. However, the trial was terminated early, so we have very little information on whether it worked.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEN1 GENE MUTATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Unispital Basel

    Basel, 4053, Switzerland

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Leflunomide (20 mg daily for 6 months)

What this could lead to

If it works, leflunomide could offer a new way to slow or shrink tumors in people with MEN1 syndrome.

What could go wrong

This was a very small, early trial that ended early, so we don't have enough data to know if it works. Leflunomide can also cause side effects like liver problems or low blood counts.

Conditions

The condition(s) this trial relates to.

multiple endocrine neoplasia type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.